Table 4. Response to induction and... | American Society of Hematology

Table 4.

Response to induction and consolidation therapy and risk-group stratification according to AIEOP-BFM ALL 2009 protocol criteria

Variable	Screening cohort						Validation cohort						P value∗
	Total	CD371^pos		CD371^neg		P value	Total	CD371^pos		CD371^neg		P value
	n	n	%	n	%	P value	n	n	%	n	%	P value
Total	843	76	9.0	767	91.0		969	84	8.7	885	91.3		.795
Prednisone response						.470						< .001
Good (PGR)	787	73	96.1	714	93.2		904	69	82.1	835	95.3		.225
Poor (PPR)	55	3	3.9	52	6.8		56	15	17.9	41	4.7		.004
NA	1	0		1			9	0		9
MCF MRD day 15						.006						< .001
<0.1%	308	15	20.5	293	38.9		284	15	19.2	269	32.6		.820
≥0.1, <10%	431	46	63.0	384	50.9		515	42	53.8	473	57.4		.149
≥10%	88	12	16.5	77	10.2		103	21	26.9	82	10.0		.147
NA	16	3		13			67	6		61
Response to induction IA						1.000						.087
CR, day 33	825	75	100.0	750	98.7		950	80	97.6	870	99.5		.618
Non-CR, day 33	10	0		10	1.3		6	2	2.4	4	0.5		.125
NA	8	1		7			13	2		11
PCR MRD final						< .001						< .001
Standard	273	11	14.9	262	35.7		337	6	7.3	331	38.5		.094
Medium	443	41	55.4	402	54.8		487	38	46.3	449	52.3		.428
MRD-SER	66	18	24.3	48	6.5		88	27	33.0	61	7.1		.646
High	25	4	5.4	21	3.0		29	11	13.4	18	2.1		.126
NA	36	2		34			28	2		26
Final risk group						< .001						< .001
Standard	277	12	15.8	265	34.6		314	6	7.1	308	35.1		.088
Medium	390	37	48.7	353	46.0		431	34	40.5	397	45.3		.416
High	176	27	35.5	149	19.4		216	44	52.4	172	19.6		.200
NA	0						8	0		8

Variable	Screening cohort						Validation cohort						P value∗
	Total	CD371^pos		CD371^neg		P value	Total	CD371^pos		CD371^neg		P value
	n	n	%	n	%	P value	n	n	%	n	%	P value
Total	843	76	9.0	767	91.0		969	84	8.7	885	91.3		.795
Prednisone response						.470						< .001
Good (PGR)	787	73	96.1	714	93.2		904	69	82.1	835	95.3		.225
Poor (PPR)	55	3	3.9	52	6.8		56	15	17.9	41	4.7		.004
NA	1	0		1			9	0		9
MCF MRD day 15						.006						< .001
<0.1%	308	15	20.5	293	38.9		284	15	19.2	269	32.6		.820
≥0.1, <10%	431	46	63.0	384	50.9		515	42	53.8	473	57.4		.149
≥10%	88	12	16.5	77	10.2		103	21	26.9	82	10.0		.147
NA	16	3		13			67	6		61
Response to induction IA						1.000						.087
CR, day 33	825	75	100.0	750	98.7		950	80	97.6	870	99.5		.618
Non-CR, day 33	10	0		10	1.3		6	2	2.4	4	0.5		.125
NA	8	1		7			13	2		11
PCR MRD final						< .001						< .001
Standard	273	11	14.9	262	35.7		337	6	7.3	331	38.5		.094
Medium	443	41	55.4	402	54.8		487	38	46.3	449	52.3		.428
MRD-SER	66	18	24.3	48	6.5		88	27	33.0	61	7.1		.646
High	25	4	5.4	21	3.0		29	11	13.4	18	2.1		.126
NA	36	2		34			28	2		26
Final risk group						< .001						< .001
Standard	277	12	15.8	265	34.6		314	6	7.1	308	35.1		.088
Medium	390	37	48.7	353	46.0		431	34	40.5	397	45.3		.416
High	176	27	35.5	149	19.4		216	44	52.4	172	19.6		.200
NA	0						8	0		8

CD371^neg, negativity of CD371 antigen at diagnosis; CD371^pos, any positivity (strong, weak, or partially positive) of CD371 antigen at diagnosis. Bold values correspond to P < .05.

CR, complete remission; MFC, multiparametric flow cytometry; PGR, prednisone good response; PPR, prednisone poor response; SER, slow early response.

∗

Comparison of variables distribution between screening (AIEOP) and validation (iBFM-FN) cohorts.

View Large

This Feature Is Available To Subscribers Only